Find all the latest information in acute lymphoblastic leukemia, arranged by types, translocations, and mutations. Listed below are recently updated categories.
Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the...
Genetic markers in the prognosis of patients with ALL
Despite much research, the mutational landscape of patients with acute lymphoblastic leukemia (ALL) remains relatively poorly characterized,...
Mixed phenotype acute leukemia: A review of diagnostic and treatment approaches
Acute leukemias generally have a distinct blast cell lineage, either myeloid (in acute myeloid leukemia [AML]), or...
Supplemental biologics license application submitted for brexucabtagene autoleucel for use in R/R B-cell ALL
Relapsed or refractory (R/R) acute lymphoblastic lymphoma (ALL) is associated with poor...
Advances of cell therapies in China: Reducing manufacturing time with FasT dual CAR T-cells
The Multiple Myeloma Hub previously summarised activities on chimeric antigen receptor (CAR) T cells in...
Development of childhood B-ALL, triggering factors, and prospective treatments
Childhood B-cell acute lymphoblastic leukemia (B-ALL), also termed B-cell precursor ALL, is a malignant disease...
Comparison of toxicities in young adults with ALL in CALGB 10403 and COG AALL0232
Superior outcomes have been reported in retrospective studies of pediatric-inspired regimens in young adults with...
What is new for CAR T-cell therapy for adult patients with ALL?
During the 3rd European CAR T-cell Meeting, the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new...
ALL by age
Adolescent and young adult
Mixed phenotype acute leukemia